The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum

A. Pintora, M.T. Tebano, A. Martire, R. Grieco, M. Galluzzo, M.L. Scattoni, A. Pëzzola, R. Coccurello, F. Felici, V. Cuomo, D. Piomelli, G. Calamandrei, P. Popoli

Abstract

The ability of CB1 receptors to regulate the release of glutamate in the striatum, together with the finding that, in experimental models of Huntington disease (HD), both endocannabinoid levels and CB1 receptor densities are reduced, has prompted the investigation on the neuroprotective role of the cannabinoids in HD. Quinolinic acid (QA) is an excitotoxin that, when injected in the rat striatum reproduces many features of HD and that acts by stimulating glutamate outflow. The aim of the present study was to test the ability of the cannabinoid receptor agonist WIN 55,212-2 to prevent the effects induced by QA in the rat striatum. In microdialysis experiments, probe perfusion with WIN 55,212-2 significantly and dose-dependently prevented the increase in extracellular glutamate induced by QA. In electrophysiological recordings in corticostriatal slices, the application of WIN 55,212-2 prevented QA-induced reduction of the field potential amplitude. Both effects of WIN 55,212-2 were prevented by the CB1 receptor antagonist AM 251. In vivo experiments, intrastriatal WIN 55,212-2 significantly attenuated the striatal damage induced by QA, although no significant effects were observed on a behavioural ground.

These data demonstrate that the stimulation of CB1 receptors might lead to neuroprotective effects against excitotoxic striatal toxicity.

Keywords: Cannabinoids; WIN 55,212-2; Quinolinic acid; Excitotoxicity; Striatum

1. Introduction

In the central nervous system, the physiological actions of cannabinoids are mediated mainly by type 1 cannabinoid (CB1) receptors (Pertwee, 1997; Freund et al., 2003). CB1 receptors are densely expressed in the basal ganglia (Herkenham et al., 1990, 1991; Mailleux and Vanderhaeghen, 1992), where they regulate glutamatergic neurotransmission under both physiological and pathological conditions (see Romero et al., 2002, for review). The ability of CB1 receptors to inhibit the synaptic release of glutamate in the striatum has been consistently reported (Gerdeman and Lovinger, 2001; Huang et al., 2001). A recent report, which demonstrates the localization of striatal CB1 receptors in the presynaptic active zone (Kofalvi et al., 2005) has provided an anatomical basis for the inhibitory effects of CB1 receptor agonists on corticostriatal glutamate release.

Since excitotoxic mechanisms are involved in the pathogenesis of several neurodegenerative diseases (Alexi et al., 2000), the ability of CB1 receptors to downregulate excitotoxic...
glutamate release might be of therapeutic interest. In particular, the finding that in Huntington disease (HD, a devastating and still untreated neurodegenerative disease) the loss of CB1 receptor binding in the basal ganglia is one of the earliest neurochemical alterations (Richfield and Herkenham, 1994; Glass et al., 2000), has prompted the investigation of the neuroprotective role of cannabinoids in HD. Interestingly, in transgenic HD mice exposed to an enriched environment, the delayed onset of HD symptoms correlated with a delayed loss of CB1 receptors (Glass et al., 2004). In models of striatal degeneration induced by mitochondrial toxins in rats, however, the idea that CB1 receptor agonists could be neuroprotective was not confirmed. Indeed, both Δ9-tetrahydrocannabinol (Δ9-THC, the naturally occurring psychoactive constituent of marijuana) and SR141716 (a selective CB1 receptor antagonist), were found to increase malonate-induced striatal lesions, while a selective CB1 receptor agonist did not show neuroprotective effects in 3-nitropropionic acid (3-NP)-lesioned rats (Lastres-Becker et al., 2003a, b). Thus, the role of CB1 receptors in HD and in HD-like striatal degeneration is far from being elucidated, and the ability of CB1 receptor agonists to exert neuroprotective effects, if any, might depend on the mechanisms responsible for striatal toxicity in a given experimental model.

Quinolinic acid (QA) is an excitotoxin that induces a marked striatal degeneration accompanied by HD-like neurochemical and functional alterations (Beal et al., 1986). In previous studies, we found that QA-induced neurotoxicity depends mainly on the ability of QA to increase extracellular glutamate levels (Popoli et al., 2002, 2003). Such a model may thus be ideal to disclose the potential effects of CB1 receptor agonists. To the best of our knowledge, however, the possible influence of cannabinoids towards QA-induced effects in the striatum has never been studied.

The aim of the present work was to verify whether CB1 receptor stimulation prevents QA-induced effects in rats. To this end, the ability of the cannabinoid agonist WIN 55,212-2 to prevent QA-induced increase in extracellular glutamate levels and QA-induced depression of the synaptic response was investigated by means of microdialysis and electrophysiological experiments, respectively. Having found that WIN 55,212-2 significantly prevented QA-induced effects, the potential in vivo neuroprotective activity of the cannabinoid receptor agonist was evaluated in QA-lesioned rats.

2. Methods

2.1. Microdialysis experiments

Under Equithesin (3 ml/kg i.p.) anesthesia, naïve Wistar rats (250–280 g) were implanted with a concentric dialysis probe (mod CMA/12, 3 mm length, Carnegie Medicine, Sweden) into the striatum. Stereotaxic coordinates in mm from bregma, sagittal suture and dura, respectively, were as follows: A = +1.7, L = +2.7, V = −6.2. Twenty-four hours after the implantation the dialysis probe was perfused at a rate of 2 µl/min with a Ringer’s solution. After a washout period of at least 90 min, samples were collected every 5 min into a refrigerated fraction collector (mod CMA/170) and then frozen until assay. Since the intraarterial injection of QA induces tremors and convulsions in rodents, these experiments were performed under general anesthesia (Equithesin). Each experimental group was made up of 4 animals. Results were expressed as percentage changes of extracellular glutamate levels induced by probe perfusion with QA (5 mM over 30 min) with respect to basal (pre-drug) values (mean of 4–6 samples collected after the induction of general anesthesia). WIN 55,212-2 (5 and 10 µM) or its vehicle (Ringer solution) were directly administered through the dialysis probe over 20 min before and along with QA perfusion. AM251 (0.5 mg/kg) was administered i.p. 30 min before starting WIN 55,212-2 perfusion. At the end of the experiment, each rat was sacrificed with an overdose of Equithesin, the brain was fixed with 4% paraformaldehyde, and coronal sections (20 µm thick) were cut to verify the probe location. The glutamate content of all samples was measured by reverse-phase high performance liquid chromatography coupled to a fluorometric detector (Perkin Elmer LC240), using a 15-min gradient elution program (methanol from 20 to 80% with 50 mM NaH2PO4 and CH3COONa), and automatic precolumn derivatization with o-phthalaldehyde and β-mercaptoethanol. Cysteic acid was used as internal standard. The concentration of the standard was linear (r² = 0.99) between 0.2 to 25 ng/10 µl. Basal glutamate levels were calculated by comparison of sample peak height with external standard peak height, both corrected for the internal standard peak height and expressed as ng/10 µl without probe recovery correction. Data were processed by two-way ANOVA (factors: treatment and time) followed by post hoc Student’s t-test.

2.2. Electrophysiological experiments

2.2.1. Extracellular recording from corticostriatal slices

Corticostriatal slices were prepared according to the method previously described by Tebano et al. (2002). Adult male Wistar rats (250–280 g) were decapitated under ether anaesthesia, the brain was quickly removed from the skull and coronal slices (300 µm thick), including the neostriatum and the neo-cortex, cut with a vibratome. Slices were maintained at room temperature (22–24 °C) in an artificial cerebrospinal fluid (ACSF) containing (mM): 126 NaCl, 3.5 KCl, 1.2 NaH2PO4, 1.3 MgCl2, 2 CaCl2, 25 NaHCO3, 11 glucose, pH 7.3, saturated with 95% O2 and 5% CO2. After incubation in ACSF for at least 1 h, a single slice was transferred to a submerged recording chamber and continuously superfused with oxygenated ACSF (33–34 °C, flow rate 2.7–3 µl/min).

Extracellular field potentials (FPs) were recorded in the mediodorsal striatum using a glass microelectrode filled with 2 M NaCl solution (pipette resistance 2–5 MΩ) and evoked by a bipolar twisted NiCr-insulated electrode (50 µm o.d.) placed in the white matter between the cortex and the striatum. The electrodes were positioned in depth where the maximal FP amplitude was observed by recording responses to the single stimuli. Stimulus intensity was then reduced to evoke a FP with an amplitude half of the maximum that could be evoked. Stimulus was delivered every 20 s (frequency 0.05 Hz, duration 100 µs) and three consecutive responses were averaged. Signals were acquired with a DAM-80 AC differential amplifier (WPI Instruments, Waltham, MA) and analysed with the “LTP software” (Anderson and Collingridge, 2001). Three consecutive responses were averaged and 10 min of stable baseline recording preceded drug application.

In order to evaluate the influence of drugs on neurotransmitter release, experiments were performed using a Paired Pulse Stimulation (PPS) protocol, in which two consecutive pulses are applied with an inter-pulse interval of 50 ms. In control conditions, this protocol elicits a condition of Paired Pulse Facilitation (PPF), in which the amplitude of the FP elicited by the second stimulus (R2) is greater than the amplitude elicited by the first stimulus (R1). The degree of PPF is quantified by the R2/R1 ratio and a modification of this ratio (R2) is greater than the amplitude elicited by the first stimulus (R1). The degree of PPF is quantified by the R2/R1 ratio and a modification of this ratio is an indication of a postsynaptic action on neurotransmitter release (Manabe et al., 1993; Schulz et al., 1994; Calabresi et al., 1997).

In each experiment, the mean basal FP amplitude (i.e. the mean from the values obtained over the 10-min period immediately preceding drug application) was calculated, and the effects of the drugs were expressed as percentage variation with respect to basal values. QA (1 mM) was applied to slices over 10 min. WIN 55,212-2 was applied over 10 min and then co-applied with QA. AM251 (2 µM) was applied 10 min before and along with WIN 55,212-2. The washout period lasted at least 30 min. Wilcoxon signed rank test and Mann–Whitney U-test were used for the statistical analysis of the data.
2.3. In vivo studies in QA-lesioned rats

In these experiments, we wanted to verify whether the ability of WIN 55,212-2 to reduce QA-induced increase in extracellular glutamate was paralleled by a neuroprotective activity in vivo.

2.3.1. Surgery and treatments

Adult male Wistar rats (250–280 g) were used. The animals were kept under standardized temperature, humidity and lighting condition, with free access to water and food. Animal care and use followed the directives of the Council of the European Communities (86/609/EEC). All efforts were made to minimize animal pain and discomfort. Animals were anesthetized with Equithesin (3 ml/kg intraperitoneally, i.p.). QA (210 nmol/0.7 μl) or vehicle (0.7 μl PBS) were bilaterally injected in the striatum (coordinates: A = +1.7; L = ± 2.7; V = −4.8 mm from bregma and dura). Groups of 7–10 animals each were treated as follows: sham-lesioned animals (intrastratal, i.s., injection of vehicle; group “veh-veh”); lesioned animals (i.s.: QA; in these animals, 4 μl of WIN55,212-2 vehicle were injected 10 min before QA; group “veh-QA”); animals treated with WIN 55,212-2 (1 μg/4 μl, 10 min before QA plus QA (group “WIN-QA”). The dose of WIN 55,212-2 to be used was calculated from the range of concentrations (5–10 μM) effective in microdialysis studies. Indeed, assuming a delivery of 10–20% of the original concentration through the dialysis probe (Battaglia et al., 2001; Cozzi et al., 2002), and considering that WIN 55,212-2 had been administered at the rate of 2 μl/min over 50 min, we estimated that about 0.5 μM of WIN 55,212-2 actually delivered to the striatum ranged from 0.5 (10% delivery) to 1 (20% delivery) μg.

2.3.2. Behavioural experiments

Two weeks after surgery, rats were subjected to the open-field test to assess motor/exploratory behaviour as well as to the plus-maze test to evaluate anxiety levels. In fact, previous experiments have shown that QA-lesioned rats show alterations in motor/exploratory behaviours when placed in a novel environment, including enhanced rearing frequency and altered responses to novelty. In addition, QA-lesioned rats show behavioural disinhibition when assessed in the plus-maze test, displaying reduced anxiety and risk assessment behaviour (Scattoni et al., 2004).

2.3.2.1. Open-field test. Spontaneous behaviour was videorecorded for 25 min in an open field arena (35 × 35 cm) made of black plexiglas with a light grey bottom subdivided by black lines into 7 × 7 cm squares. A novel object was introduced in the arena after 20 min from the beginning of the observation. Recordings were then scored by an observer blind to the treatments received by each animal, and the following behavioural categories were analysed by “The Observer” (Wageningen, NL) a software package for collection and analysis of observational data: number of crossings (crossing the square limits with both forepaws), frequency of rearing behaviour, and time spent in contact with the novel object.

2.3.2.2. Plus maze test. The elevated plus-maze comprised two open arms and two closed arms that extended from a common central platform. The apparatus was constructed from Plexiglas (black floor, clear walls) and elevated to a height of 60 cm above the floor level. Rats were individually placed on the central platform facing a closed arm and allowed to freely explore the maze for 10 min. Videotapes were scored by a highly trained observer using the above mentioned software. Conventional measures were the frequencies of total, open and closed entries (arm entry = all four paws into an arm), and percentage of time spent in open, closed and central parts of the maze [e.g. (time open/session duration) × 100].

2.3.3. Evaluation of the striatal damage

The striatal damage induced by QA was evaluated as previously described (Popoli et al., 2002, 2004). Briefly, four weeks after the lesion, the animals (QA only, N = 10; WIN 55,212-2 + QA, N = 7) were decapitated, the brains removed and immediately frozen. For each brain, serial 20-μm coronal sections were cut on a cryostat microtome, stained with Cresyl violet and examined by light microscopy. In QA-lesioned animals, a series of at least five consecutive sections showing a maximal lesion was identified; within this series, the mean amount of ventricular enlargement (ventricular area in μm²) was measured. Images were captured by a colour digital camera and analysed by the IASS software (Delta Sistemi, Rome, Italy).

3. Results

3.1. WIN 55,212-2 prevents QA-induced increase in extracellular glutamate levels

Mean basal glutamate levels in the striatum were 1.66 ± 0.03 μM. As previously reported, probe perfusion with 5 mM QA significantly increased striatal glutamate outflow (Fig. 1). This effect was reduced and abolished by direct striatal perfusion of 5 and 10 μM WIN 55,212-2, respectively (Fig. 1). Two-way ANOVA showed that both time (P < 0.0001) and treatment (P < 0.0001) factors, as well as their interaction (P < 0.001) were significant. Basal glutamate levels were not affected by WIN 55,212-2. The selective CB₁...
receptor antagonist AM251 (0.5 mg/kg i.p., 30 min before starting QA perfusion) prevented the inhibitory effects of WIN 55,212-2 10 μM towards QA (Fig. 1). When administered alone, AM251 did not influence basal or QA-stimulated extracellular levels of glutamate (N = 4, not shown).

3.2. WIN 55,212-2 prevents QA-induced FP reduction in corticostriatal slices

In electrophysiological experiments in corticostriatal slices, WIN 55,212-2 (2 μM over 20 min) elicited a significant depression of FP amplitude (−43.05 ± 3.32%; N = 5, P < 0.05) which reached 25.47 ± 1.27% of basal after 30 min of washout (P = 0.001 vs control) (Fig. 2). In agreement with the known ability of WIN 55,212-2 to inhibit presynaptic neurotransmitter release, WIN-induced reduction of FP amplitude was accompanied by an increase in the magnitude of PPF measured through the R2/R1 ratio (1.21 ± 0.5 and 1.74 ± 0.13 in control conditions and after WIN application, respectively; N = 5, P < 0.03) (Fig. 2C). Both effects of WIN 55,212-2 (FP depression and increase in the R2/R1 ratio) were completely prevented by the selective CB1 receptor antagonist AM251 2 μM (Figs. 2B, C). When applied alone, AM251 did not influence synaptic transmission (data not shown).

In order to evaluate the influence of CB1 receptor stimulation on QA-induced effects, a concentration of WIN 55,212-2 (1 μM) which did not significantly influence on its own the FP amplitude (−14.30 ± 7.42%; N = 8, P > 0.05) or the R2/R1 ratio (1.30 ± 0.08 vs. 1.25 ± 0.47, N = 8, NS, Fig. 3C) was used. Consistently with previous observations from our group (Tebano et al., 2002; Popoli et al., 2004), the application of QA (1 mM over 10 min, N = 12) to corticostriatal slices induced a strong reduction of FP amplitude (−91.28 ± 2.15%), followed by a partial recovery after washout (−54.1 ± 6.39%; P < 0.001 vs control, Figs. 3A, B). The effects elicited by QA on corticostriatal slices appeared to depend, at least in part, on the stimulation of presynaptic glutamate release. QA, in fact, reduced the R2/R1 ratio under a protocol of PPS (control: 1.254 ± 0.046, QA: 1.117 ± 0.044, N = 12 P < 0.02 vs control, Fig. 3C). Both QA-induced FP disappearance and R2/R1 reduction were significantly attenuated by WIN 55,212-2 1 μM, a concentration which did not influence the FP on its own (FP amplitude: −51.79% ± 12.37, N = 8, P > 0.02 vs QA alone; R2/R1 ratio: 1.283 ± 0.041, N = 8, P < 0.02 vs QA alone, Figs. 3B, C). The inhibitory effects of WIN 55,212-2 were completely blocked by AM251 2 μM (P < 0.005 vs WIN + QA, N = 5; Figs. 3A–C). AM251 alone did not influence QA effects (N = 3, not shown). The recovery of the FP response after washout was not significantly influenced by WIN 55,212-2 (mean FP amplitude at the recovery: 45.90 ± 6.39 and 61.91 ± 10.74% after QA alone and WIN + QA, respectively; P > 0.05; N = 12 Fig. 3B), probably because of the high lipophilicity of the drug which can not be easily washed out from the slices (Brown et al., 2003; Melis et al., 2004). Indeed, in a separate series of experiments we found that, when WIN 55,212-2 was applied over 20 min (i.e. the same period as in the experiments performed with WIN + QA), and then washed out, the FP amplitude decreased up to 67.19 ± 7.56% of basal (N = 4) 30 min after the washout. Thus, it is very likely that, although...
WIN 55,212-2 can prevent QA-induced FP reduction, its intrinsic ability to induce a delayed reduction of FP amplitude may mask the former effect.

3.3. In QA-lesioned rats, WIN 55,212-2 does not effectively prevent behavioural abnormalities while showing a slight neuroprotective effect

3.3.1. Behavioural experiments

Locomotor activity assessed by crossing frequency was not significantly affected by QA lesion, and crossing frequency decreased throughout the four 5-min blocks in agreement with a normal motor habituation profile (data not shown). However, QA lesion affected open rearing, a behavior associated with exploration and visual scanning of a novel environment: rearing was significantly increased in veh-QA in comparison to veh-veh rats on sessions 2, 3 and 4 ($P < 0.05$ after post hoc comparisons performed on the interaction treatment × session). Although rats pretreated with WIN 55,212-2 (1 μg i.s.) did not significantly differ from veh-QA, in these animals a normalization of rearing frequency was observed in session 4 (Fig. 4A).

As previously described (Scattoni et al., 2004), a novel object was placed in the center of the arena at the end of the 20-min-open field test and the animals’ behaviour observed for 5 min (session 5). The main treatment effect on time spent in object exploration did not reach statistical significance [$F(2,22) = 2.92, P = 0.07$]. However, post-hoc comparisons yielded a significant difference between veh-veh and veh-QA rats ($P < 0.05$): QA lesioned rats spent less time in contact with the novel object than did control rats. Animals pretreated with WIN 55,212-2 showed the same reduction in object exploration as did veh-QA group (Fig. 4B).

QA lesion tended to decrease anxiety-related responses in the plus-maze. As shown in Fig. 4C, time spent in the open arms was significantly increased in veh-QA but not in WIN-QA rats in comparison to veh-veh controls.

3.4. Neuropathological analyses

A marked ventricular enlargement was visible in QA-lesioned animals. In animals pretreated with WIN 55,212-2, the mean ventricular enlargement was slightly though significantly attenuated (Fig. 5).

4. Discussion

The main findings of the present study are as follows: i) WIN 55,212-2 prevented QA-induced glutamate outflow and FP reduction in a concentration-dependent way; ii) the effects of WIN 55,212-2 were fully prevented by AM251, thus indicating a selective involvement of CB1 receptors; and iii) the ability of WIN 55,212-2 to prevent QA-induced increase in extracellular glutamate is associated with a weak neuroprotective effect in QA-lesioned rats.

The ability of WIN 55,212-2 to prevent QA-stimulated glutamate outflow in striatal microdialysis is reported here for the
outflow. This is in agreement with the findings that its effects becoming evident only in conditions of stimulated used here, WIN 55,212-2 did not affect basal glutamate levels, Huang et al., 2001). At least in the range of concentrations from corticostriatal synapses (Gerdeman and Lovinger, 2001; Kofalvi et al., 2005). It should be noted, however, that the inhibitory effects of CB1 receptors on glutamate outflow may not be a general mechanism in the brain, since systemic administration of low doses of WIN 55,212-2 has been reported to increase basal extracellular levels of glutamate in the rat cortex (Ferraro et al., 2001). To add further complexity to the matter, at concentrations higher than those used by us, the CB1 receptor antagonist AM251 was found to reduce glutamate release as well (Kofalvi et al., 2005). In spite of these contrasting observations, however, our results confirm the widely accepted notion that cannabinoids exert an inhibitory control on corticostriatal glutamate release. Interestingly, cannabinoids can also modulate glutamate outflow through non-CB1 mechanisms, since they still decreased glutamate release in the hippocampus of CB1-deficient mice (Hajos et al., 2001; Kofalvi et al., 2003). In our experiments, however, the ability of AM251 to abolish the effects of WIN 55,212-2 clearly suggests the involvement of CB1 receptors in the modulation of striatal glutamate release. It should be noted, nonetheless, that the block by AM251 might be not a definite index of a CB1-mediated effect. Indeed, a recent report showed that in CB1−/− mice, AM251 decreased the inhibitory effect of WIN 55,212-2 on glutamate release (Kofalvi et al., 2005), thus indicating the possible existence of a non-CB1, AM251-sensitive cannabinoid receptor. Although the above mentioned findings require caution, it is important to point out that in the striatum of CB1−/− mice concentrations of WIN 55,212-2 higher than those effective in the rat striatum or in the mice hippocampus (20 μM) were required to inhibit glutamate release (Kofalvi et al., 2005). Moreover, although WIN 55,212-2 could still stimulate GTP-γS binding in some brain areas from CB1-deficient mice, this did not apply to the striatum (Breivogel et al., 2001; Monory et al., 2002). Thus, although some important species- and region-related differences seem to exist in the pharmacology of cannabinoid receptors, it is very likely that effects induced in the rat striatum by 1–2 μM WIN 55,212-2 and blocked by AM251 can be considered as CB1-mediated.

In corticostriatal slices, WIN 55,212-2 reduced the FP amplitude. This effect, which was completely prevented by the CB1 receptor antagonist AM251, was likely mediated by an inhibition of presynaptic glutamate release, as suggested by the increase in the magnitude of PPF. These findings are fully consistent with previous striatal electrophysiology studies on the effects of Δ9-THC, WIN 55,212-2 or the CB1 receptor agonist HU-210 (Gerdeman and Lovinger, 2001; Huang et al., 2001; Brown et al., 2003). In agreement with previous studies from our group (Popoli et al., 2004; Tebano et al., 2002), the strong reduction of the FP amplitude induced by 1 mM QA can be considered as a toxic effect, since the electrical response only partially recovered after washout. Such an effect, although qualitatively similar to that induced by WIN 55,212-2, can not be ascribed to an inhibition of presynaptic glutamate release. Indeed, as suggested by the reduction of the R2/R1 ratio under a protocol of PPS, QA rather increases the release of glutamate. Thus, while the reduction of FP amplitude induced by WIN 55,212-2 may be ascribed to a depression of corticostriatal glutamatergic transmission, a different

Fig. 4. WIN 55,212-2 does not significantly influence the behavioural abnormalities induced by QA. (A) Rearing frequency throughout the four sessions of a 20 min open-field test, (B) time spent in object investigation during the last session of the open-field, (C) time spent in open arms of a plus-maze by rats receiving bilateral striatal injection of either WIN 55,212-2 (WIN) or vehicle solution (VEH) 10 min before intrastriatal administration of quinolinic acid (QA) or vehicle (VEH). Rats were assessed two weeks after the lesion. n = VEH + VEH = 8; VEH + QA = 10; WIN + QA = 7. Data are means ± SEM. * = P < 0.05 versus VEH + VEH controls.

first time. This finding is in line with previous reports showing that CB1 receptor stimulation reduced the release of glutamate from corticostriatal synapses (Gerdeman and Lovinger, 2001; Huang et al., 2001). At least in the range of concentrations used here, WIN 55,212-2 did not affect basal glutamate levels, its effects becoming evident only in conditions of stimulated outflow. This is in agreement with the findings that Δ9-THC reduced K+-stimulated, but not basal, glutamate release in striatal slices (Brown et al., 2003). Moreover, at concentrations comparable to those used here (≈1–2 μM), WIN 55,212-2 did not affect resting glutamate outflow but reduced, through a CB1-mediated mechanism, evoked glutamate release in rat striatal synaptosomes (Kofalvi et al., 2005). It should be noted,
mechanism has to be invoked for QA. In this case, the enhanced glutamate levels (most probably achieved by the activation of NMDA receptors, which in turn stimulates presynaptic glutamate release) may reduce the FP amplitude as a consequence of neuronal depolarization. Moreover, and perhaps even more importantly, QA may act by stimulating postsynaptic NMDA receptors, thus leading to neuronal depolarization and consequently loss of the drive for postsynaptic potential. Whatever the mechanism, we found, in nice agreement with the microdialysis results, that WIN 55,212-2 prevented QA-induced effects and that the CB1 receptors are involved in the action of WIN 55,212-2.

The finding that WIN 55,212-2 prevented the effects of QA on glutamate outflow (microdialysis) as well as on the R2/R1 ratio (electrophysiology) confirms the ability of cannabinoids to downregulate excitotoxic glutamate release. Given the key role of excitotoxicity in the pathogenesis of striatal neurodegenerative disorders, the above finding prompted us to verify the possible neuroprotective effects of the CB1 receptor agonist in a model of striatal excitotoxicity. Specifically, we took advantage of the model of QA-induced striatal damage, in which a chronic and progressive phenotype is thought to be triggered by early excitotoxic events (Popoli et al., 2002, 2004; Scattoni et al., 2004). Although such experiments were performed in a limited number of animals, at the dose used here WIN 55,212-2 significantly, though modestly, reduced the amount of QA-induced ventricular enlargement (an established index of the lesion, see Popoli et al., 2004).
Such a protective activity was however not paralleled by a clear functional effect. Indeed, no significant reduction of QA-induced behavioural effects was observed in rats pretreated with WIN 55,212-2. It would then seem that the anatomical protection provided by WIN 55,212-2 is too modest to have a functional impact. In agreement with this conclusion, in previous experiments aimed at evaluating the neuroprotective activity of other treatments, we found that the ability to prevent QA-induced behavioural abnormalities was paralleled by a reduction of 50% or more of the striatal damage (Popoli et al., 2002, 2004). The apparent discrepancy found between the microdialysis experiments (in which WIN 55-212,2 clearly prevented QA effects) and the studies in lesioned animals (in which the effects of WIN 55-212,2 were modest to absent) might depend on the fact that the dose of QA used to induce a clear striatal degeneration was necessarily higher than that used to acutely stimulate glutamate outflow. In any case, and although further studies with different doses of CB1 receptor ligands are needed to draw a firm conclusion on the true neuroprotective potential of WIN 55,212-2, the present results do suggest that CB1 receptor activation may provide protection against striatal excitotoxicity. Whether such results may imply a role of CB1 receptors in HD remains to be determined in appropriate experimental models. In particular, considering that cannabinoids have shown neuroprotective effects in cells expressing mutated huntingtin (Aiken et al., 2004), and that altered CB1 gene transcription has been proposed as one of the toxic functions of mutant huntingtin (McCaw et al., 2004), the effects of CB1 receptor agonists should be evaluated in transgenic HD mice.

Acknowledgments

This paper is dedicated to the memory of our beloved colleague Rosaria (“Sara”) Reggio. This work was supported by grants 4AN/F7 from the Ministry of Health and FIRB 2006.

References

Aiken, C.T., Tobin, A.J., Schweitzer, E.S., 2004. A cell-based screen for drugs to treat Huntington’s disease. Neurobiology Disease 16, 546–555.
Alexi, T., Borlongan, C.V., Faull, R.L.M., Williams, C., Clark, R.G., Gluckman, P.D., Hughes, P.E., 2000. Neuroprotective strategies for basal ganglia degeneration: Parkinson’s and Huntington’s disease. Progress in Neurobiology 60, 409–470.
Anderson, W.W., Collingridge, G.L., 2001. The LTP Program: a data acquisition program for on-line analysis of long-term potentiation and other synaptic events. Journal of Neuroscience Methods 108, 71–83.
Battaglia, G., Bruno, V., Pisani, A., Centonze, D., Catania, M.V., Calabresi, P., Nicoletti, F., 2001. Selective blockade of type-1 metabotropic glutamate receptors induces neuroprotection by enhancing gabaergic transmission. Molecular Cellular Neuroscience 17, 1071–1083.
Beal, M.F., Kowall, N.W., Ellison, D.W., Mazurek, M.F., Swartz, K.J., Martin, J.B., 1986. Replication of the neurochemical characteristics of Huntington’s disease by quinolinic acid. Nature 321, 168–171.
Breivogel, C.S., Griffin, G., Di Marzo, V., Martin, B.R., 2001. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Molecular Pharmacology 60, 55–163.
Brown, T.M., Brotchie, J.M., Fitzjohn, S.M., 2003. Cannabinoids decrease corticostriatal synaptic transmission via an effect on glutamate uptake. Journal of Neuroscience 23, 11073–11077.
Calabresi, P., Centonze, D., Pisani, A., Bernardi, G., 1997. Endogenous adenosine mediates the presynaptic inhibition induced by aglycemia at corticostriatal synapses. Journal of Neuroscience 17, 4509–4516.
Cozzi, A., Meli, E., Carlì, V., Pellellicciari, R., Moroni, F., Pellegrini-Giapponi, D.E., 2002. Metabotropic glutamate 1 (mGlU1) receptor antagonists enhance GABAergic neurotransmission: a mechanism for the attenuation of post-ischemic injury and epileptiform activity? Neuropharmacology 43, 119–130.
Ferraro, L., Tomasini, M.C., Cassano, T., Bebe, B.W., Siniscalchi, A., O’Connor, W.T., Magee, P., Tanganelli, S., Cuorno, V., Antonelli, T., 2001. Cannabinoid receptor agonist WIN 55,212-2 inhibits rat cortical dialysate gamma-aminobutyric acid levels. Journal of Neuroscience Research 66, 298–302.
Freund, T.F., Katona, I., Piomelli, D., 2003. Role of endogenous cannabinoids in synaptic signaling. Physiology Reviews 83, 1017–1066.
Gerdesen, G., Lovinger, D.M., 2001. CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. Journal of Neurophysiology 85, 468–471.
Glass, M., Dragunow, M., Faull, R.L., 2000. The pattern of neurodegeneration in Huntington’s disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington’s disease. Neuroscience 97, 505–519.
Glass, M., van Dellen, A., Blakemore, C., Hannan, A.J., Faull, R.L., 2004. Delayed onset of Huntington’s disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors. Neuroscience 123, 207–212.
Hajos, N., Ledent, C., Freund, T.F., 2001. Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience 106, 1–4.
Herkenham, M., Lynn, A.B., Little, M.D., Johnson, M.R., Melvin, L.S., de Costa, B.R., Rice, K.C., 1990. Cannabinoid receptor localization in brain. Proceedings National Academy of Science USA 87, 1932–1936.
Herkenham, M., Lynn, A.B., de Costa, B.R., Richfield, E.K., 1991. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Research 547, 267–274.
Huang, C.C., Lo, S.W., Hsu, K.S., 2001. Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons. Journal of Physiology 532, 731–748.
Kofalvi, A., Vizi, E.S., Ledent, C., Sperlagh, B., 2003. Cannabinoids inhibit the release of [3H]glutamate from rodent hippocampal synaptosomes via a novel CB1 receptor-independent action. European Journal of Neuroscience 18, 1973–1978.
Kofalvi, A., Rodrigues, R.J., Ledent, C., Mackie, K., Vizi, E.S., Cunha, R.A., Sperlagh, B., 2005. Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis. Journal of Neuroscience 25, 2874–2884.
Lastres-Becker, I., Bizat, N., Boyer, F., Hantraye, P., Brouillet, E., Fernandez-Ruiz, J., 2003a. Effects of cannabinoids in the rat model of Huntington’s disease generated by an intrastriatal injection of malonate. Neuroreport 14, 813–816.
Lastres-Becker, I., de Miguel, R., Makriyannis, A., Di Marzo, V., Fernandez-Ruiz, J., 2003b. Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington’s disease. Journal of Neurochemistry 84, 1097–1109.
Mailleux, P., Vanderhaeghen, J.J., 1992. Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience 48, 655–668.
Manabe, T., Wylie, D.J., Perkel, D.J., Nicoll, R.A., 1993. Modulation of synaptic transmission and long-term potentiation: effects on paired pulse facilitation and EPSC variance in the CA1 region of the hippocampus. Journal of Neurophysiology 70, 1451–1459.
McCaw, E.A., Hu, H., Gomez, G.T., Hebb, A.L., Kelly, M.E., Denovan-Wright, E.M., 2004. Structure, expression and regulation of the
cannabinoid receptor gene (CB1) in Huntington’s disease transgenic mice. European Journal of Biochemistry 271, 4909–4920.

Melis, M., Pistis, M., Perra, S., Muntoni, A.L., Pillolla, G., Gessa, G.L., 2004. Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. Journal of Neuroscience 24, 53–62.

Monory, K., Tzavara, E.T., Lexime, J., Ledent, C., Parmentier, M., Borsodi, A., Hanoune, J., 2002. Novel, not adenylyl cyclase-coupled cannabinoid binding site in cerebellum of mice. Biochemistry Biophysics Research Communication 292, 231–235.

Pertwee, R.G., 1997. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacology Therapeutics 74, 129–180.

Popoli, P., Pintor, A., Domenici, M.R., Frank, C., Tebano, M.T., Pëzzola, A., Scarchilli, L., Quarta, D., Reggio, R., Malchiodi-Albedi, F., Falchi, M., Massotti, M., 2002. Blockade of striatal adenosine A1A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum. Journal of Neuroscience 22, 967–1975.

Popoli, P., Frank, C., Tebano, M.T., Potenza, R.L., Pintor, A., Domenici, M.R., Nazzicone, V., Pëzzola, A., Reggio, R., 2003. Modulation of glutamate release and excitotoxicity by adenosine A2A receptors. Neurology 61, S69–S71.

Popoli, P., Pintor, A., Tebano, M.T., Frank, C., Pepponi, R., Nazzicone, V., Greco, R., Pëzzola, A., Reggio, R., Minghetti, L., De Berardinis, M.A., Martire, A., Potenza, R.L., Domenici, M.R., Massotti, M., 2004. Neuroprotective effects of the mGlu5R antagonist MPEP towards quinolinic acid-induced striatal toxicity: involvement of pre- and post-synaptic mechanisms and lack of direct NMDA blocking activity. Journal of Neurochemistry 89, 1479–1489.

Richfield, E.K., Herkenham, M., 1994. Selective vulnerability in Huntington’s disease: preferential loss of cannabinoid receptors in lateral globus pallidus. Annals of Neurology 36, 577–584.

Romero, J., Lastres-Becker, I., de Miguel, R., Berrendero, F., Ramos, J.A., Fernandez-Ruiz, J., 2002. The endogenous cannabinoid system and the basal ganglia. biochemical, pharmacological, and therapeutic aspects. Pharmacology Therapeutics 95, 137–152.

Scattoni, M.L., Valanzano, A., Popoli, P., Pëzzola, A., Reggio, R., Calamandrei, G., 2004. Progressive behavioural changes in the spatial open-field in the quinolinic acid rat model of Huntington’s disease. Behavioural Brain Research 152, 375–383.

Schulz, P.E., Cook, E.P., Johnston, D., 1994. Changes in paired-pulse facilitation suggest presynaptic involvement in long-term potentiation. Journal of Neuroscience 14, 1566–1578.

Tebano, M.T., Domenici, M.R., Popoli, P., 2002. SCH 58261 differentially influences quinolinic acid-induced effects in striatal and in hippocampal slices. European Journal of Pharmacology 450, 253–257.